PSHP 2026 Residency Conference

Purpose: To implement a pharmacist-driven protocol which allows for the step-down of IV ceftriaxone to PO antibiotics for hospitalized patients with uncomplicated and complicated urinary tract infections to help improve transition time.  
Methods: A prospective study will be conducted from February 23, 2026 to May 12, 2026, using data collected from EPIC. The included patients will be age 18 and older with a UTI diagnosis, presence of stones, obstruction, strictures, TURP, prostatitis, stents, associated bacteremia, indwelling urinary catheters, pregnancy and before/after genitourinary procedure. Patients will be excluded if they have asymptomatic bacteriuria, secondary diagnosis for another infection, renal abscess, or are immunocompromised.  
The primary endpoint is transition time from IV to PO antibiotics. Secondary endpoints include length of stay, 30-day UTI readmission rates, total length of therapy, antibiotic selection and dosing. The endpoints will be compared to a retrospective analysis from May 1, 2025, to June 30, 2025, to assess if a pharmacist-driven protocol allowed for a timely transition to oral antibiotics and/or a reduction in any of the secondary endpoints.
Results: TBD 
Conclusion: TBD 
IRB Approval: IRB approval is not required as this research is categorized as a process improvement project.